Tela Bio, Inc. (TELA) Stock Price & Analysis

Tela Bio, Inc. (TELA) rose 5.19% to USD 0.82 as of September 8, 2026 at 12:05 UTC, according to Nexqual real-time market data.

TELA last closed at USD 0.82; the session ranged USD 0.79–0.84 on volume of 115,649 shares. Market capitalization is —, with a 52-week range of USD 0.5–1.73 (NGM). Source: Nexqual, September 8, 2026 at 12:05 UTC.

Key Statistics (as of September 8, 2026 at 12:05 UTC)

Technical Analysis (TELA)

Nexqual's technical model rates TELA "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 12:05 UTC.

From Tela Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)

Key Strengths & Strategy (as disclosed to the SEC)

• We believe we can enhance the productivity of our sales force by improving customer segmentation and targeting, implementing and further refining our proprietary training programs, leveraging support from our medical education and medical affairs functions to drive physician awareness, education and clinical understanding of our products, and utilizing engagement analytics to support further product development and enhancement opportunities.
• Our OviTex PRS products are designed with a patented corner-lock stitch pattern designed to resist deformation and to control the degree and direction of stretching of the product. 13 Table of Contents Our capabilities in polymer science, biologics, textile engineering and analytical testing enable us to quickly design innovative products for development and manufacture.
• The key elements of our strategy include: 18 Table of Contents Our Products Our Technology Platform Our advanced reinforced tissue matrix technology consists of multiple layers of minimally-processed, decellularized extracellular matrix derived from ovine rumen with interwoven polymer fibers in a unique embroidered pattern.
• Trade Secrets We seek to protect our proprietary rights through a variety of methods, including confidentiality agreements and proprietary information agreements with suppliers, employees, consultants and others who may have access to our proprietary information.

Partnerships

• In September 2023, we entered into a distribution agreement with Advanced Medical Solutions Limited, a company registered in England, to distribute their LIQUIFIX Hernia Mesh Fixation Devices (LIQUIFIX FIX8™ and LIQUIFIX Precision™).
• In addition, we believe our exclusive manufacturing and long-term supply and license agreement with Aroa (the "Aroa License") creates a 8 Table of Contents competitive advantage by allowing us to secure an exclusive supply of ovine rumen at a low cost.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 12:05 UTC. This page is informational and not investment advice.